Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

This pharmacokinetics study is examining how a drug called pevifoscorvir (ALG-000184) — being developed for hepatitis B — moves through the body in people with impaired kidney function compared to healthy individuals. Understanding this is important before using the drug more broadly. **You may be eligible if...** - You are 18–75 years old with a BMI between 17.5–40 and weigh more than 50 kg - You are either a healthy person with normal kidney function, OR someone with any degree of kidney impairment (not due to acute nephritic syndrome) - If female, you are not of childbearing potential, or you and your partner agree to use highly effective contraception - If in the kidney impairment group, your condition and medications have been stable for at least 28 days **You may NOT be eligible if...** - You have acute kidney disease (acute nephritic syndrome) - Your other health metrics (ECG, vital signs, labs) do not meet the study criteria - You are pregnant or at risk of pregnancy without contraception Talk to your doctor to see if this trial is right for you.